VIP (Vasoactive Intestinal Peptide)

Vasoactive Intestinal Peptide (VIP) is a naturally occurring 28-amino-acid neuropeptide distributed widely across the gut, nervous system, and immune tissue, where it functions as a vasodilator and immune-signaling molecule. It has drawn research interest in the context of chronic inflammatory response syndrome (CIRS) and mold-related illness, autoimmune conditions, and pulmonary disease. Much of the human clinical data come from small studies and case series rather than large controlled trials. VIP is not an approved standalone therapy for these uses and remains investigational outside of narrow clinical contexts. Reported benefits include studied in chronic inflammatory response syndrome and mold-illness protocols, explored for anti-inflammatory immune modulation, investigated for potential support of pulmonary and vascular function.

Reported ranges run 25-100 mcg. A low protocol is 25 mcg up to 4 times daily, and a high protocol is 100 mcg up to 4 times daily. This is reference information, not a dosing recommendation.

Very short, on the order of 1-2 minutes in circulation. That is what sets the dosing frequency, and it is why the timing guidance is as directed by your clinician.

Subcutaneous: into fat, under the skin. Clinical research has also explored nasal (intranasal) administration; injectable subcutaneous use is more common in current research protocols.

variable, often several months in supervised protocols on, followed by reassessed based on clinical markers off. Used in some structured protocols only after underlying triggers such as environmental mold exposure are addressed; cycling is protocol-specific and supervised

Reported side effects include flushing or facial warmth, transient low blood pressure, fatigue, injection site irritation, limited large-scale human safety data. Evidence level for this compound is moderate evidence.